Abstract CT295: Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors
Ciara M. Kelly, Reinhard von Roemeling, Monali Banerjee, Viswatej Avutu et autres
us, gb (code pays fourni par la source)